spacer
spacer

PDBsum entry 3q5h

Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Hydrolase/hydrolase inhibitor PDB id
3q5h

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
337 a.a.
Ligands
NAG-NAG
RX6 ×2
Metals
_CL ×6
Waters ×168
PDB id:
3q5h
Name: Hydrolase/hydrolase inhibitor
Title: Clinically useful alkyl amine renin inhibitors
Structure: Renin. Chain: a, b. Fragment: unp residues 67-406. Synonym: angiotensinogenase. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: ren, renin. Expressed in: homo sapiens. Expression_system_taxid: 9606. Expression_system_cell_line: hek 293.
Resolution:
2.16Å     R-factor:   0.226     R-free:   0.268
Authors: Z.Wu,B.M.Mckeever
Key ref: L.Jia et al. (2011). Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility. Acs Med Chem Lett, 2, 747-751. PubMed id: 24900262 DOI: 10.1021/ml200137x
Date:
28-Dec-10     Release date:   30-Nov-11    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
P00797  (RENI_HUMAN) -  Renin from Homo sapiens
Seq:
Struc:
406 a.a.
337 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class: E.C.3.4.23.15  - renin.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Cleaves Leu-|- bond in angiotensinogen to generate angiotensin I.

 

 
DOI no: 10.1021/ml200137x Acs Med Chem Lett 2:747-751 (2011)
PubMed id: 24900262  
 
 
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
L.Jia, R.D.Simpson, J.Yuan, Z.Xu, W.Zhao, S.Cacatian, C.M.Tice, J.Guo, A.Ishchenko, S.B.Singh, Z.Wu, B.M.McKeever, Y.Bukhtiyarov, J.A.Johnson, C.P.Doe, R.K.Harrison, G.M.McGeehan, L.W.Dillard, J.J.Baldwin, D.A.Claremon.
 
  ABSTRACT  
 
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.
 

 

spacer

spacer